Amylyx Pharmaceuticals Reports Positive Phase 3 Results
CAMBRIDGE, Mass., August 18, 2026 Amylyx Pharmaceuticals, Inc. announced positive topline results from the Phase 3 LUCIDITY clinical trial...
endocrine disorders
Advertisement
Amylyx to Report Phase 3 Avexitide Results August 18
CAMBRIDGE, Mass., August 17, 2026 Amylyx Pharmaceuticals, Inc. announced that it will report topline results from the Phase 3...
Neurocrine Reports Two-Year CRENESSITY Data Showing Improved Growth in Pediatric CAH
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has presented new two-year data from its Phase 3 CAHtalyst® Pediatric study,...
Pentixapharm Advances PANDA Phase 3 Study After FDA Clearance
BERLIN, Germany – June 9, 2026 Pentixapharm Holding AG has achieved a major regulatory milestone after receiving U.S. Food...
Foresee Pharmaceuticals Reports Positive CPP Phase 3 Data
TAIPEI, Taiwan, May 27, 2026 Foresee Pharmaceuticals has announced the successful completion of its Casppian Phase 3 clinical trial...
Advertisements
Galvanize Expands Aliya PEF Portfolio With FDA Clearance of Aliya EX
REDWOOD CITY, Calif., May 18, 2026 Galvanize Therapeutics has announced that the U.S. Food and Drug Administration (FDA) granted...
Dechra Wins FDA Approval for Canine CosACTHen®
OVERLAND PARK, Kan., May 19, 2026 Dechra has announced that the U.S. Food and Drug Administration (FDA) approved CosACTHen®...
Crinetics Submits Brazil MAA for Palsonify Drug
San Diego, USA – March 26, 2026 Crinetics Pharmaceuticals announced the submission of a Marketing Authorization Application (MAA) to...
UK Approves Once-Monthly Octreotide Injection for Acromegaly Care
Lund, Sweden — August 28, 2025 — The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval...
Advertisement
